EL7.AI
StocksMedium•31 July 2026•
1 min read

Neurocrine Biosciences Beats Q2 Estimates and Raises Annual Guidance

Key Facts

1Neurocrine Biosciences reported Q2 2026 revenues of $959 million, a 39% year-over-year increase.
2Non-GAAP earnings per share reached $2.85, significantly beating the consensus estimate of $2.26.
3The company raised its 2026 net sales guidance for INGREZZA to a range of $2.825 billion to $2.875 billion.

In a move reflecting strong performance within the biotech sector, Neurocrine Biosciences announced exceptional financial results for the second quarter of 2026. The company reported revenues of $959 million, representing a 39% year-over-year increase, while non-GAAP earnings per share reached $2.85, significantly beating consensus estimates of $2.26. This outperformance was driven by robust commercial execution and a 15% year-over-year increase in sales of its flagship product, INGREZZA.

Following this momentum, the company raised its 2026 net sales guidance for INGREZZA to a range of $2.825 billion to $2.875 billion, signaling management's confidence in sustained demand. According to market data and analyst reports, Citigroup raised its price target for NBIX to $249 while maintaining a "Buy" rating. The company also strengthened its portfolio by completing the acquisition of Soleno Therapeutics in May 2026, supporting its expansion strategy in neurological treatments.

Looking at the economic calendar, there are no direct upcoming catalysts for the company in the next seven days; however, markets remain focused on the ongoing impact of the Fed Interest Rate Decision from July 29, 2026, on the growth and healthcare sectors.